NEW YORK (GenomeWeb News) – Enzo Biochem has filed a shelf registration to separately offer up to $50 million of its securities and another $18 million of its common stock.

Enzo filed two prospectuses in a Form S-3 with the US Securities and Exchange Commission on Thursday. In one, the New York-based life science reagents and diagnostic testing firm said it may offer from time to time its common stock, preferred stock, depositary shares, debt securities, warrants, and units totaling no more than $50 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.